Navigation Links
LS9 Secures $25 Million in Latest Round of Funding
Date:9/24/2009

LS9, Inc., the Renewable Petroleum Company™, today announced it successfully completed a $25 million round of funding. Participating investors included CTTV Investments LLC, the venture capital arm of Chevron Technology Ventures LLC; Flagship Ventures; Khosla Ventures and Lightspeed Venture Partners.

South San Francisco, CA (PRWEB) September 24, 2009 -- LS9, Inc., the Renewable Petroleum Company™, today announced it successfully completed a $25 million round of funding. Participating investors included CTTV Investments LLC, the venture capital arm of Chevron Technology Ventures LLC; Flagship Ventures; Khosla Ventures and Lightspeed Venture Partners.

In May this year, LS9 announced a strategic partnership with Procter & Gamble to support the joint development and commercialization of LS9 technology to produce key chemicals used within the P&G portfolio of consumer products.

"LS9 is proud to attract recognized leaders in consumer products and transportation fuels," said Bill Haywood, CEO of LS9. "This clearly illustrates the future potential of LS9 in both the sustainable chemicals and renewable transportation fuels sectors."

LS9's revolutionary technology uses a one-step fermentation process to convert renewable plant-based materials into a portfolio of UltraClean™ fuels and high-value, sustainable chemicals. "LS9 represents one of the cleanest and most efficient technologies available in the production of high-value, low-carbon, cost effective fuels, and this funding will accelerate our ability to demonstrate commercial level production," said Stephen del Cardayre, Vice President, Research and Development, LS9.

LS9 is currently producing UltraClean™ Diesel at its pilot facility. UltraClean™ Diesel has achieved U.S. and Brazilian performance standards for on-road use, and achieves an 85% reduction in green house gas emissions. In addition, LS9 UltraClean™ Diesel contains no carcinogens, such as benzene, and only trace amounts of sulfur.

LS9's technology also makes it possible to create superior products that can uniquely achieve optimal overall performance. LS9 has demonstrated its ability to modify the genetic makeup of its microorganisms and precisely tailor LS9 end products to have improved fuel properties such as cetane, volatility, oxidative stability and cold-flow. LS9 will have demonstration scale production of UltraClean™ Diesel in 2010.

In addition to low-carbon transportation fuels, LS9's one-step fermentation process is capable of producing chemicals used in making industrial and consumer products. LS9 previously announced a partnership with Procter & Gamble to jointly develop and commercialize LS9 technology for use in the production of key consumer chemicals within the Procter & Gamble portfolio.

For more information about LS9 products and capabilities, please visit www.ls9.com.

About LS9
LS9, Inc., the Renewable Petroleum Company™, is a privately-held industrial biotechnology company pursuing the commercial development of renewable fuels and chemicals. LS9 is applying synthetic biology to produce proprietary biofuels that are compatible with existing fuel distribution and consumer infrastructure, as well as high-value industrial chemicals. LS9 is the pioneer in the commercial development of fermentation derived hydrocarbon biofuels and its patent-pending Renewable Petroleum(TM) products are custom engineered in the lab to address immediate market needs for clean energy alternatives to petroleum. The company was founded in 2005 and venture capital firms Flagship Ventures, Khosla Ventures, and Lightspeed Venture Partners have provided funding to date. LS9 is headquartered in South San Francisco, California. For more information about LS9 products and capabilities, please visit www.ls9.com.

###

Read the full story at http://www.prweb.com/releases/2009/09/prweb2936734.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences Secures Committed Equity Financing Facility
2. OpenQ Secures Investment from Leading Mid-Atlantic Venture Firm
3. Cappella Inc. Secures $17.3 Million Series C Investment
4. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria
5. Sinobiopharma Secures Rights to Seven Key Patents
6. Aerovance Secures $38 Million in Equity Financing
7. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
8. Pearl Therapeutics Secures $8 Million in Debt Financing
9. Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
10. Sopherion Therapeutics Secures $55 Million in Series C Funding
11. Northwest Biotherapeutics Secures $700,000 Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... Lithuania, announced today that they have entered into a multiyear collaboration to identify ... CRISPR researchers with additional tools for gene editing across all applications. , Under ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board ... Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced ... for membership in ARCS Alumni Hall of Fame . ASTER Labs is ...
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and ... rebranding initiative announced today. The bold new look is part of a transformation ... moves into a significant growth period. , It will also expand its service offering ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
Breaking Biology News(10 mins):